DPP ‐4 inhibitor sitagliptin treatment results in altered myocardial metabolic proteome and oxidative phosphorylation in a swine model of chronic myocardial ischemia
Physiological Reports · 2024
DOI: 10.14814/phy2.15976 ↗At a glance
Journal article in Physiological Reports, 2024. Written by Dwight D Harris and 7 co-authors. Institution: Division of Cardiothoracic Surgery, Department of Surgery, Cardiovascular Research Center, Rhode Island Hospital, Alpert Medical School of Brown Univ…. Major MEDLINE topics: Dipeptidyl-Peptidase IV Inhibitors, Myocardial Ischemia. Cited 1 times so far (Crossref); 36 references. The full text is freely available (open access, CC BY 4.0). Funded by: NHLBI NIH HHS, NIGMS NIH HHS, Foundation for the National Institutes of Health.
Abstract (original language)
Small animal models have shown improved cardiac function with DPP‐4 inhibition, but many human studies have shown worse outcomes or no benefit. We seek to bridge the gap by studying the DPP‐4 inhibitor sitagliptin in a swine model of chronic myocardial ischemia using proteomic analysis. Thirteen Yorkshire swine underwent the placement of an ameroid constrictor on the left coronary circumflex artery to model chronic myocardial ischemia. Two weeks post‐op, swine received either sitagliptin 100 mg daily (SIT, n = 5) or no drug (CON, n = 8). After 5 weeks of treatment, swine underwent functional measurements and tissue harvest. In the SIT group compared to CON, there was a trend towards decreased cardiac index ( p = 0.06). The non‐ischemic and ischemic myocardium had 396 and 166 significantly decreased proteins, respectively, in the SIT group compared to CON (all p < 0.01). This included proteins involved in fatty acid oxidation (FAO), myocardial contraction, and oxidative phosphorylation (OXPHOS). Sitagliptin treatment resulted in a trend towards decreased cardiac index and decreased expression of proteins involved in OXPHOS, FAO, and myocardial contraction in both ischemic and non‐ischemic swine myocardium. These metabolic and functional changes may provide some mechanistic evidence for outcomes seen in clinical studies.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Division of Cardiothoracic Surgery, Department of Surgery, Cardiovascular Research Center, Rhode Island Hospital, Alpert Medical School of Brown University, Providence, Rhode Island, USA.
ORCID profiles: Cynthia M Xu, M Ruhul Abid, Frank W Sellke
Funding
- NHLBI NIH HHS
- NIGMS NIH HHS
- Foundation for the National Institutes of Health
Cite
APA
Harris, D. D., Sabe, S. A., Broadwin, M., Bellam, K., Xu, C. M., Li, J. W., Abid, M. R., & Sellke, F. W. (2024). DPP ‐4 inhibitor sitagliptin treatment results in altered myocardial metabolic proteome and oxidative phosphorylation in a swine model of chronic myocardial ischemia. Physiological Reports. https://doi.org/10.14814/phy2.15976
Vancouver
Harris DD, Sabe SA, Broadwin M, Bellam K, Xu CM, Li JW, et al. DPP ‐4 inhibitor sitagliptin treatment results in altered myocardial metabolic proteome and oxidative phosphorylation in a swine model of chronic myocardial ischemia. Physiological Reports. 2024. doi:10.14814/phy2.15976
BibTeX
@article{Harris2024,
author = {Harris, Dwight D and Sabe, Sharif A and Broadwin, Mark and Bellam, Krishna and Xu, Cynthia M and Li, Janelle W and Abid, M Ruhul and Sellke, Frank W},
title = {DPP ‐4 inhibitor sitagliptin treatment results in altered myocardial metabolic proteome and oxidative phosphorylation in a swine model of chronic myocardial ischemia},
journal = {Physiological Reports},
year = {2024},
doi = {10.14814/phy2.15976}
}
EUVIMED